Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for IDEAYA Biosciences (IDYA) over the last 5 years, with Q3 2025 value amounting to $2.2 million.

  • IDEAYA Biosciences' Current Deferred Revenue changed N/A to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $8.6 million for FY2022, which is 8577.5% down from last year.
  • IDEAYA Biosciences' Current Deferred Revenue amounted to $2.2 million in Q3 2025.
  • IDEAYA Biosciences' 5-year Current Deferred Revenue high stood at $77.6 million for Q1 2021, and its period low was $1.4 million during Q3 2023.
  • Moreover, its 4-year median value for Current Deferred Revenue was $30.7 million (2022), whereas its average is $33.5 million.
  • In the last 5 years, IDEAYA Biosciences' Current Deferred Revenue tumbled by 2810.09% in 2021 and then plummeted by 9357.71% in 2023.
  • IDEAYA Biosciences' Current Deferred Revenue (Quarter) stood at $60.2 million in 2021, then crashed by 85.78% to $8.6 million in 2022, then plummeted by 83.2% to $1.4 million in 2023, then soared by 50.52% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $1.4 million for Q3 2023, and $2.8 million during Q2 2023.